Treatment of Prolactinoma (Knosp Grade 0–1) When First-Line Therapy Fails to Normalize Prolactin

This protocol applies to patients with a microprolactinoma or a well-circumscribed macroprolactinoma (Knosp grade 0 or 1) who have not achieved normalization of serum prolactin after first-line treatment.

Clinical Scenario

The tumor is classified as Knosp grade 0 or 1 — a microprolactinoma or a well-circumscribed macroprolactinoma. In this setting, surgical resection and dopamine agonist therapy represent co-equal first-line options, typically evaluated together in a multidisciplinary discussion that weighs the curative potential and risks of each approach.

First-Line Failure Condition

First-line treatment consisted of surgical resection (transsphenoidal surgery) by an expert pituitary neurosurgeon, or cabergoline (a dopamine agonist) — discussed as co-equal initial options. This protocol is indicated when normalization of serum prolactin levels (surgical remission) was not achieved, or when recurrence has occurred after initial response.

Next-Line Approach

The next step involves dopamine agonist-based therapy following surgical intervention — the specific agent, sequencing, and full decision algorithm are available in the complete protocol.

Dosing, alternative strategies, and all clinical decision points remain in the structured regimen.

Treatment Goal

Normalization of serum levels of prolactin.

Instant Access to Structured Evidence-Based Regimens

References

Surgical resection of microprolactinomas and well-circumscribed macroprolactinomas (Knosp grade 0 and 1) by an experienced neurosurgeon offers a high chance of cure, is cost-effective and avoids long-term dopamine agonist treatment.

For microprolactinomas and well-encased macroprolactinomas (Knosp grade 0 and 1), the curative potential and risks of surgery should be discussed with patients in a multidisciplinary setting prior to medical treatment initiation (strong).

Recurrence or lack of remission should prompt dopamine agonist dose increase or consideration for surgery; intolerability can be addressed by switching to a different dopamine agonist or consideration for surgery.

Dopamine agonist therapy is highly effective at lowering serum levels of prolactin, improving clinical consequences of hyperprolactinaemia and reducing adenoma size (strong).

DOI: 10.1038/s41574-023-00886-5 View source ↗